The Role of TextRAd on Detection of Liver Metastasis in Rectal Cancer
1 other identifier
observational
113
1 country
1
Brief Summary
This is a retrospective analysis of all patients diagnosed with LARC who received NCRT and had MRI scans between 2003-2014 at East Suffolk and North Essex NHS Foundation Trust. Region of interest was drawn around the tumor or its location on T2 MRI images. Six texture parameters were systematically extracted from Textural histograms of post-treatment scans. These parameters were examined to determine their ability to predict local recurrence and distant metastases through Kaplan-Meier survival curves and log-rank tests.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jul 2019
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 18, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 18, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
July 18, 2021
CompletedFirst Submitted
Initial submission to the registry
May 26, 2022
CompletedFirst Posted
Study publicly available on registry
June 1, 2022
CompletedJune 1, 2022
May 1, 2022
2 years
May 26, 2022
May 26, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Local recurrence of rectal cancer
120 months
Interventions
Texture analysis (TA) is a novel imaging biomarker that can assess heterogeneity in MRIs by measuring grey-level intensities distribution. This study hypothesizes that TA of MRI is an imaging biomarker that can predict local recurrence and distant metastasis.
Eligibility Criteria
Patients diagnosed with locally advanced rectal cancer (LARC) includes neoadjuvant chemoradiotherapy (NCRT) followed by surgical resection
You may qualify if:
- All subjects must have MRI post-Chemotherapy treatment to detect the response to Neoadjuvant treatment and compare it to pre-treatment scans to easily determine if there were a posttreatment liver metastasis.
- Locally advanced rectal cancer (LARC) = MRI stage: T3/T4 and/or N1/N0.
You may not qualify if:
- Distant metastases.
- Synchronous tumour.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
East Suffolk and North Essex NHS Foundation Trust
Ipswich, IP4 5PD, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 26, 2022
First Posted
June 1, 2022
Study Start
July 18, 2019
Primary Completion
July 18, 2021
Study Completion
July 18, 2021
Last Updated
June 1, 2022
Record last verified: 2022-05
Data Sharing
- IPD Sharing
- Will not share